glp-1 dual agonist GIPR/GLP-1R therapies for diabetes and weight loss– Chemistry, Physiology and Clinical application Schematic illustration of monoagonists, dual
Description
Patients should plan for the program to end on December 31, 2027 unless extended
Cardiovascular disease: risk assessment and reduction, including lipid modification
GLP-1 receptor agonists and cardiovascular outcome trials: An update
This is especially important in elderly patients or those on diuretics, where dehydration could lead to acute kidney injury or hypotension [11]
A randomized controlled trial by Mann J et al
